Cancer Med:CHADS2分数可预测前列腺癌根治术后缺血性卒中的发生

2015-11-26 phylis 译 MedSci原创

前列腺癌患者卒中发生的风险增加,但是绝对卒中发生率与年龄和共发病相关。在行政索赔数据集,应用Charlson共发病指数分数(CCIS)评估风险。这篇研究评估CHADS2分数和CCIS分数对前列腺癌患者发生卒中的预测价值。这篇研究数据来源于台湾全民健康保险研究数据库(NHIRD)。1997年到2011年间,研究者选出非房颤(AF)患者5414名,这些患者患有前列腺癌病行前列腺癌根治术后。应用CHAD

前列腺癌患者卒中发生的风险增加,但是绝对卒中发生率与年龄和共发病相关。在行政索赔数据集,应用Charlson共发病指数分数(CCIS)评估风险。这篇研究评估CHADS2分数和CCIS分数对前列腺癌患者发生卒中的预测价值。

这篇研究数据来源于台湾全民健康保险研究数据库(NHIRD)。1997年到2011年间,研究者选出非房颤(AF)患者5414名,这些患者患有前列腺癌病行前列腺癌根治术后。应用CHADS2分数和CCIS分数将5年缺血性卒中发生的风险分层。自入院日,开始随访受试者直至缺血性卒中发生、死亡及5年随访期结束。

显著研究的缺血性卒中发生率为1.7%。与CCIS分数相比(CCIS = 0至1, 1.6%, CCIS = 2-3:1.7%,CCIS≥4:3.8%;AUC = 0.520),缺血性卒中的发生于CHADS2分数有更好的相关(CHADS2评分为0到1:0.02%,CHADS2评分= 2 至3:13.9%,CHADS2评分≥4:44.4%,;AUC = 0.978)。

研究结果显示,CHADS2分数较高的患者行前列腺癌根治术的前列腺癌患者,卒中发生的风险较高,CHADS2分数可用来预测缺血性卒中的发生。CHADS2分数较高,建议对前列腺癌患者进行心血管风险评估和处理。

原文出处:

Yang YW,  Lee SS, Chen CC4, et al.  CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy.  Cancer Med. 2015, Nov 21.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
    2015-11-28 Handyuan

    赞一个

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]
    2015-11-28 jeanqiuqiu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1986556, encodeId=c09b19865567d, content=<a href='/topic/show?id=5822325417e' target=_blank style='color:#2F92EE;'>#前列腺癌根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32541, encryptionId=5822325417e, topicName=前列腺癌根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 16 03:10:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806052, encodeId=7518180605216, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 26 07:10:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029492, encodeId=2de22029492cb, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Nov 10 04:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892707, encodeId=c5051892e07f9, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 17 09:10:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44032, encodeId=f46d4403243, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Sat Nov 28 19:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399707, encodeId=72dd1399e0793, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586019, encodeId=6ddc1586019ce, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606734, encodeId=906c1606e3492, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 28 13:10:00 CST 2015, time=2015-11-28, status=1, ipAttribution=)]

相关资讯

NEJM:奥拉帕尼(Lynparza)将为三成晚期前列腺癌患者带来福音

前列腺癌出自前列腺的恶性肿瘤,若细胞的基因突变导致增殖失控就会患上癌症。昨日英国《金融时报》报道援引伦敦癌症研究院表态称,去年生物制药企业阿斯利康(AstraZeneca)获得欧盟批准用于治疗卵巢癌的药物奥拉帕尼(Lynparza)将为25%-30%的晚期前列腺癌患者带来福音。上述报道提到,在《新英格兰医学期刊》( New England Journal o

Am J Clin Nutr:血液中类胡萝卜素、视黄醇、生育酚对前列腺癌的影响

有研究表明血液中类胡萝卜素、视黄醇或生育酚会导致前列腺癌风险增加,但是此类研究样本均较少,不能提供精确的评估,尤其是与该疾病的分级分期相关联系。因此研究者对已存在的研究进行合并分析,评估以上几种物质与前列腺癌风险的关系,同时探究该联系是否会因为疾病的分期分级而发生变化,或者其他因素会对探究结果产生影响。该研究共纳入了15项研究共计 11,239名研究对象,包括 1654 名晚期,1741 名进展期

PSA的筛查率下降,是否就会有更多的男性死于前列腺癌?

PSA的筛查率下降,是否就会有更多的男性死于前列腺癌?长久以来,医生、科学家和公共健康专家们一直在警告PSA筛查对前列腺癌的筛查弊大于利:研究显示,与2005年相比,如今接受血液检测的男性人数明显下降。那么问题来了:是否越少的男性接受PSA检测,越多的男性死于前列腺癌?据发表于《美国医学会杂志》的一篇社论认为答案是肯定的。一项研究报道显示,2012年接受PSA检测的男性人数较2011年少335

液态活检预测前列腺癌耐药性,NGS助力探讨分子机制

【导读】11月4日《科学转化医学》杂志上的一则研究表明,利用下一代测序可评估前列腺癌患者血液中雄激素受体(AR)基因的变化,有助于解释去势难治性前列腺癌对雄性激素的抵抗性。 11月4日《科学转化医学》杂志上的一则研究表明,利用下一代测序可评估前列腺癌患者血液中雄激素受体(AR)基因的变化,有助于解释去势难治性前列腺癌对雄性激素的抵抗性。 该研究由意大利特兰托大学及伦敦癌症研究中心研究人员主导,

Lancet Oncology:前列腺癌筛查,STHLM3模型更靠谱

目前临床长常用前列腺特异性抗原 (PSA) 筛查前列腺癌,但是该指标具有很高的假阳性率,会导致不必要的前列腺活检和过度诊断。研究者欲开发和验证一个更好的筛查高危前列腺癌( Gleason得分≥7分)患者的方式。该研究纳入了50-69岁没有前列腺癌的男性。对所有纳入人群检测预定义的STHLM3模型(包括血浆标志物:PSA, free PSA, intact PSA, hK2, MSMB, MIC1;

Integr Cancer Ther:前列腺癌患者练习瑜伽,生活质量可明显提高

宾夕法尼亚大学佩雷尔曼医学院的Neha Vapiwala博士和他的同事们最近在肿瘤学会的国际会议上提出了他们的研究结果。